Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments

Share Capital (Tables)

v3.23.2
Share Capital (Tables)
 6 Months Ended
Jun. 30, 2023
Share Capital [Abstract]  
Schedule of Shares Issued Granted Options In the six months ended June 30, 2023 and 2022, the Company granted options as follows:
    Six months ended June 30, 2023
    Number of options granted     Exercise
price
range		     Vesting
period		   Expiration
Employees     104,500     $ 7.5     4 years   10 years
    Six months ended June 30, 2022
    Number of options granted     Exercise
price
range		     Vesting
period
range		   Expiration
Employees     398,000     $ 9.22     4 years   10 years
Directors     217,000     $ 9.22     4 years   10 years
Schedule of Fair Value of Options Granted to Employees on the Date of Grant Was Computed Using athe Black-Scholes Model The fair value of options granted on the date of grant was computed using the Black-Scholes model. The underlying data used for computing the fair value of the options are as follows:
    Six months ended
June 30		  
    2023     2022  
Value of ordinary share   $ 7.5     $ 9.07-9.22  
Dividend yield     0 %     0 %
Expected volatility     74.1 %     67.28%-67.95 %
Risk-free interest rate     0.36 %     1.72%-3.03 %
Expected term     6.11 years       6.11 years  

 
Schedule of Summarizes the Number of Options Granted to Employees Under the Option Plan The following table summarizes the number of options granted to employees and directors under the 2010 Plan for the six months period ended June 30, 2023:
    Number of
options		     Weighted
average
exercise
price		  
Options outstanding at the beginning of the period     1,868,749     $ 7.85  
Granted     104,500       7.5  
Exercised     (29,163 )     4.43  
Forfeited or expired     (95,559 )     9.43  
Options outstanding at the end of the period     1,848,527     $ 7.8  
Options exercisable at the end of the period     1,105,189     $ 7.35  
    Number of
options		     Weighted
average
exercise
price		  
Options outstanding at the beginning of the period     15,416     $ 16.04  
Granted    
-
      
-
  
Exercised     (3,750 )     5.07  
Forfeited or expired    
-
      
-
  
Options outstanding at the end of the period     11,666     $ 16.45  
Options exercisable at the end of the period     6,329     $ 9.81  
Schedule of Share-Based Compensation The following table illustrates the effect of share-based compensation on the statements of operations:
    Six months ended
June 30		     Three months ended
June 30		  
    2023     2022     2023     2022  
Cost of revenue   $ 19     $ 2     $ 11     $ 2  
Research and development     307       374       121       173  
General, administrative and marketing     526       647       206       400  
    $ 852     $ 1,023     $ 338     $ 575